Financial Data and Key Metrics Changes - Total revenue for the second quarter was $213 million, a 3% increase year over year, driven by a 3% increase in both Medical and Industrial segments [23][24] - Non-GAAP gross margin was 36%, up from 33% in the same quarter last year, reflecting improved volume and productivity gains [9][27] - Adjusted EBITDA for the quarter was $34 million, compared to $25 million in the previous year [9][23] - Cash from operations was strong at $17 million, with total cash, cash equivalents, and marketable securities at $226 million, up $36 million year over year [9][31] Business Line Data and Key Metrics Changes - Medical segment revenues were $154 million, constituting 72% of total revenue, while Industrial segment revenues were $59 million, making up 28% [24] - Sales in the Medical segment were led by strong global sales of CT tubes, with fluoroscopy, oncology, mammography, and dental modalities all performing above their respective sales trends [10] - The Industrial segment saw strong demand, particularly in global security screening, which drove sales of cargo inspection components and systems [11] Market Data and Key Metrics Changes - Americas revenue increased by 2%, EMEA revenues were flat, and APAC revenues increased by 8%, primarily due to increased sales in China [24] - Sales in China increased by 25% year over year but declined by 11% compared to the prior quarter, with China sales constituting 15% of total sales [24][25] Company Strategy and Development Direction - The company plans to mitigate the impact of tariffs through various strategies, including localizing manufacturing and pursuing operational strategies to reduce costs for customers [12][14][22] - The focus remains on long-term growth strategies based on innovation and cost leadership, with continued investment in regional manufacturing operations [22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about demand trends across the business, despite headwinds from tariffs, and noted that no orders have been canceled from the $316 million backlog [21][22] - The company anticipates a sales impact of approximately $20 million in China due to tariffs, with a potential EPS reduction of $0.15 to $0.20 in the third quarter [32] Other Important Information - The company plans to use restricted cash from a senior secured debt offering to repay outstanding convertible notes upon maturity in June [9][31] - The gross debt outstanding at the end of the quarter was $570 million, with a net debt leverage ratio of approximately 2.1 times adjusted EBITDA [31] Q&A Session Summary Question: Update on orders in China and customer purchasing behavior - Management noted that while some customers are pausing purchases, they continue to place orders for essential products, particularly for high-end tubes [35][36][40] - Customers are trying to manage inventory while awaiting potential tariff resolutions [41][42] Question: Impact of the $25 million cargo inspection order on capacity - Management confirmed that lead times for delivery are typically 120 to 180 days, with civil works affecting timelines [47][48][50] Question: Clarification on tariff impacts and revenue drivers in China - The majority of revenue in China comes from CT tubes, and customers are currently delaying orders while exploring alternatives [57][58][62] Question: Trends outside of China and overall demand - Management indicated that demand trends outside of China remain strong, with broad-based strength in both medical and industrial segments [78][80] Question: Updates on the India plant and tariff mitigation strategies - The company is accelerating activities in India to help mitigate tariff impacts and is qualifying suppliers from India [85][86] Question: Anticipated impact of tariffs on industrial business - Tariffs are expected to impact the industrial business as well, but the sales of industrial products into China are minimal [94] Question: Potential for near-term tariff relief and its impact - Management indicated that any near-term relief could lead to immediate recovery in sales, depending on timing [102][103]

Financial Data and Key Metrics Changes - Total revenue for the second quarter was $213 million, a 3% increase year over year, driven by both Medical and Industrial segments [22][23] - Non-GAAP gross margin was 36%, up from 33% in the same quarter last year, reflecting improved volume and productivity gains [7][25] - Adjusted EBITDA for the quarter was $34 million, compared to $25 million in the previous year [7][22] - Cash from operations was strong at $17 million, with total cash, cash equivalents, and marketable securities reaching $226 million, an increase of $36 million year over year [8][29] Business Line Data and Key Metrics Changes - Medical segment revenues were $154 million, accounting for 72% of total revenue, while Industrial segment revenues were $59 million, making up 28% [23][24] - Sales in the Medical segment increased, particularly in CT tubes, fluoroscopy, oncology, mammography, and dental modalities, while radiography sales were below trend [9][10] - The Industrial segment saw strong demand, particularly in cargo inspection systems and non-destructive inspection applications [10][19] Market Data and Key Metrics Changes - Americas revenue increased by 2%, EMEA revenues were flat, and APAC revenues rose by 8%, primarily due to increased sales in China [23] - Sales in China increased by 25% year over year but declined by 11% compared to the previous quarter, representing 15% of total sales [24] Company Strategy and Development Direction - The company plans to mitigate tariff impacts by localizing manufacturing and pursuing operational strategies [12][21] - Continued investment in regional manufacturing operations and supply chain capabilities is a priority [21] - The company remains committed to innovation and cost leadership as part of its long-term growth strategy [21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about demand trends across the business, despite headwinds from tariffs [20] - The company does not anticipate restructuring in its China business and has not seen order cancellations in its backlog [20] - Future sales impacts from tariffs are expected to be temporary, with recovery anticipated in Q4 [67][68] Other Important Information - The company plans to use restricted cash to repay outstanding convertible notes upon maturity in June [8][29] - Gross debt outstanding at the end of the quarter was $570 million, with a net debt leverage ratio of approximately 2.1 times adjusted EBITDA [29] Q&A Session Summary Question: Update on orders in China and customer purchasing behavior - Management noted that while some customers are pausing purchases, orders for essential tubes continue, and customers are lobbying for tariff exemptions [35][36][41] Question: Impact of the $25 million cargo inspection order on delivery capacity - Management confirmed that lead times for delivery are typically 120 to 180 days, with civil works affecting timelines [46][48] Question: Clarification on tariff impacts and revenue drivers in China - Management indicated that the majority of revenue in China comes from CT tubes, and customers are currently holding off on orders due to tariffs [55][61] Question: Trends outside of China and overall demand - Management reported broad-based strength in both medical and industrial segments, with positive order intake rates [78] Question: Updates on the India plant and tariff mitigation strategies - Management confirmed that activities in India are proceeding as planned, with efforts to accelerate operations to mitigate tariff impacts [86] Question: Passing on tariff costs to customers - Management stated that they plan to pass tariff costs directly to customers without markups, and discussions are ongoing [88][89] Question: Anticipated impact of potential near-term tariff relief - Management suggested that any near-term relief could lead to immediate recovery in sales, depending on timing [103] Question: Timeline for reaching margin accretiveness in the inspection business - Management indicated that it may take at least two years for the inspection business to become margin accretive [111]

Core Viewpoint - Koss Corporation reported a slight increase in net sales for the third quarter of fiscal year 2025, but continued to experience net losses, highlighting challenges in certain market segments and the impact of external factors such as tariffs on product costs [2][4]. Financial Performance - Net sales for the three months ended March 31, 2025, were $2,781,006, an increase of $143,400, or 5.4%, compared to $2,637,606 for the same period in the prior year [2]. - For the nine months ended March 31, 2025, net sales reached $9,539,960, reflecting an increase of $168,292, or 1.8%, over the prior year's $9,371,668 [3]. - The net loss for the third quarter of fiscal year 2025 was $316,742, slightly higher than the net loss of $313,780 for the same quarter in the previous year [2]. - The net loss for the nine months ended March 31, 2025, was $642,135, showing improvement compared to a net loss of $840,542 for the same period in the prior year [3]. Sales and Market Dynamics - A significant increase in sales to distributors in Europe and Asia, driven by new product success, was a key factor in the overall sales improvement for the fiscal year-to-date [4]. - Direct-to-consumer (DTC) sales contributed to sales growth, but a nearly 60% drop in sales to the education markets due to project postponements and lower domestic distributor sales offset some of the gains [4]. Margin and Cost Analysis - Margin improvement of over 600 basis points during the first nine months of fiscal year 2025 was attributed to the adverse impact on prior year's margins from higher transit costs [4]. - The write-off of obsolete products during the current year partially offset margin gains [4]. Strategic Considerations - The company is closely monitoring recent tariff announcements that could significantly impact product costs, particularly since a substantial portion of its products are sourced from China [4]. - A strategic response is being developed to mitigate potential adverse effects on operations and financial condition [4].

Financial Data and Key Metrics Changes - Net revenue for the first quarter was $162 million, up 10% from last year, marking the twentieth consecutive quarter of year-over-year growth since the IPO in 2020 [8][20] - Gross profit for the first quarter rose to $62.5 million, or 38.5% of net revenue, compared to 39.8% of net revenue last year [21] - Net income decreased 11.2% to $16.9 million, or $0.37 per diluted share, compared to $19 million, or $0.43 per diluted share for the same period last year [23] - Adjusted EBITDA for the first quarter was $27.5 million, or 16.9% of net revenue, down from 19.7% in the prior year [23] Business Line Data and Key Metrics Changes - The Butter business saw robust growth, with first-quarter net revenue up 41% year-over-year [9] - Volume-related growth for egg products was below trend due to supply constraints, but demand remains strong [10][18] - The company added approximately 25 new family farms to its network in the first quarter, increasing the total to over 450 farms [14] Market Data and Key Metrics Changes - Brand awareness reached 31% by the end of the first quarter, a five-point increase since the beginning of the year [10] - The company is currently in only 11.3% of U.S. households, indicating significant growth potential [12] Company Strategy and Development Direction - The company aims to achieve $1 billion in net revenue by 2027, with a gross margin target of about 35% and an adjusted EBITDA margin of 12% to 14% [14][30] - Investments are being made in supply chain infrastructure and new facilities to increase capacity and support innovation [15][30] - The company plans to implement a modest low double-digit price increase for shell egg products to offset anticipated cost impacts from tariffs [17] Management's Comments on Operating Environment and Future Outlook - Management expects volume growth to improve beginning in the second quarter as new farms ramp up production [18] - The company remains confident in its ability to deliver on financial targets despite macroeconomic uncertainties and tariff impacts [27][28] - Management believes that consumer loyalty and brand strength will insulate the company from potential negative impacts of tariffs [28][87] Other Important Information - The company is on track to remediate a material weakness in internal controls related to revenue recognition, with no revenue inconsistencies found [26] - Capital expenditures for fiscal year 2025 are projected to be in the range of $50 million to $60 million, primarily for new facilities and digital transformation projects [28][29] Q&A Session Summary Question: Impact of price increase on retailer pricing - Management indicated that pricing is primarily focused on protecting gross margins and ensuring strong relationships with retail partners [39][40] Question: Current egg supply and retailer orders - Management noted that the category is still not fully servicing demand, with elevated orders from retailers [41][42] Question: Volume growth expectations for the year - Management expects volume growth to accelerate as new farms come online, with Q2 serving as a transition point [48] Question: Impact of tariffs on costs - Management confirmed that while there will be some cost pressures due to tariffs, the price increase is expected to cover these impacts [60][63] Question: Retail distribution increase - The increase in reported distribution from 24,000 to 26,000 stores is attributed to a change in data providers rather than a significant increase in new retailers [67][68] Question: Consumer behavior amidst macro uncertainty - Management observed that brand loyalty remains strong, with consumers less willing to trade down even in challenging economic conditions [76][87] Question: Dynamics of the butter business supply chain - Management discussed the transition in the butter supply chain and the expectation of consistent growth without bottlenecks [79]

Financial Data and Key Metrics Changes - Net revenue for Q1 2025 was $162 million, an increase of 10% year-over-year, marking the twentieth consecutive quarter of growth since the IPO in 2020 [6][18] - Gross profit rose to $62.5 million, representing 38.5% of net revenue, down from 39.8% the previous year due to increased investments and less efficient operations [19][20] - Net income decreased by 11.2% to $16.9 million, or $0.37 per diluted share, compared to $19 million, or $0.43 per diluted share in Q1 2024 [21] - Adjusted EBITDA for Q1 2025 was $27.5 million, or 16.9% of net revenue, down from 19.7% in the prior year [21] Business Line Data and Key Metrics Changes - The Butter business saw robust growth with net revenue up 41% year-over-year [7] - Egg product demand remains strong, but supply constraints have limited volume growth [8][16] - The company added approximately 25 new family farms in Q1 2025, increasing its network to over 450 farms [13] Market Data and Key Metrics Changes - Brand awareness reached 31% by the end of Q1 2025, a five-point increase since the beginning of the year [9] - The company is currently in 11.3% of U.S. households, indicating significant room for growth [11] Company Strategy and Development Direction - The company aims to achieve $1 billion in net revenue by 2027, with a gross margin target of about 35% and an adjusted EBITDA margin of 12% to 14% [14][28] - Investments in supply chain infrastructure and farm expansion initiatives are expected to support sustained growth [14][29] - The company plans to implement a modest price increase for shell egg products to offset anticipated cost impacts from tariffs [15][26] Management's Comments on Operating Environment and Future Outlook - Management expects volume growth headwinds to ease in Q2 2025, leading to reaccelerated net revenue growth [16] - The company remains confident in its ability to navigate macroeconomic uncertainties and consumer behavior changes due to its strong brand loyalty [84] - Management reiterated its full-year guidance for net revenue of at least $740 million, representing at least 22% growth compared to 2024 [24][25] Other Important Information - The company is on track with its digital transformation initiative, with the launch of a new ERP system updated to early fall 2025 [27] - The company is addressing a material weakness in internal controls related to revenue recognition, with no revenue inconsistencies found [23] Q&A Session Summary Question: Impact of price increase on retailer pricing - Management indicated that pricing is primarily aimed at protecting gross margins and maintaining strong relationships with retail partners [39] Question: Current egg supply and retailer orders - Management noted that while the category is improving, supply constraints still exist, and elevated orders from retailers reflect ongoing demand [41] Question: Volume growth expectations for the year - Management expects volume growth to accelerate as new farms come online, with Q2 serving as a transition point [48] Question: Impact of tariffs on pricing and costs - Management confirmed that while tariffs could impact costs, the price increase is expected to cover these impacts [62] Question: Retail distribution increase clarification - The increase in reported distribution from 24,000 to 26,000 stores was due to a change in data providers rather than a significant increase in new retailers [67] Question: Consumer behavior amidst macro uncertainty - Management observed that brand loyalty remains strong, with consumers less likely to trade down even in challenging economic conditions [84]

Financial Data and Key Metrics Changes - Total reported revenue for Q1 2025 was $693 million, down from $711 million in the prior year, primarily due to lower COVID and donor screening revenue [18] - Excluding COVID and donor screening, the company achieved a mid single-digit revenue growth of 6% [18] - Adjusted EBITDA margin improved by 450 basis points year over year to 23%, with adjusted diluted EPS increasing by 68% to $0.74 [24][25] Business Line Data and Key Metrics Changes - Labs business, accounting for 54% of total revenue, grew by 7%, driven by clinical chemistry and immunoassay testing [10] - Immunohematology business grew by 4%, maintaining its global leadership position [10] - Point of Care business represented 25% of Q1 revenue and grew by 8% excluding COVID, with strong flu sales leading to an 18% year-over-year growth [10] - Molecular Diagnostics business grew by 11% excluding COVID, with ongoing clinical trials for the Savanna respiratory panel [11] Market Data and Key Metrics Changes - Revenue from the "Other" region (Japan, Asia Pacific, Latin America) grew by 12%, driven by a 17% increase in Labs revenue [19] - North America revenue declined by 6% due to lower COVID revenue and donor screening wind down, but grew by 5% when excluding these factors [19] - Europe, Middle East, and Africa grew by 9%, while China revenue remained flat, primarily due to order timing and decreased Triage revenue [20] Company Strategy and Development Direction - The company is focused on a narrow set of strategic initiatives, including increasing platform content and utility, expanding margins, and enhancing commercial execution [11] - Plans to realize $100 million in annualized cost savings, with $50 million expected in the first half of 2025 [12] - The company aims to maintain its manufacturing footprint and continue investing in U.S.-based manufacturing and R&D [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and operational discipline, highlighting strong Q1 results and ongoing initiatives [9] - The company anticipates potential tariff impacts of $30 million to $40 million in 2025 but believes mitigation plans will offset these impacts [15] - Full-year 2025 financial guidance remains unchanged, with expectations for total reported revenue between $2.6 billion and $2.81 billion [27] Other Important Information - The company has invested nearly $1 billion in U.S.-based manufacturing and R&D over the past three years [13] - Adjusted free cash flow for Q1 2025 was $47 million, representing 29% of adjusted EBITDA [26] - The company plans to refinance its debt in the second half of 2025 or early 2026, depending on market conditions [31] Q&A Session Summary Question: Can you elaborate on the tariff impact and pricing actions? - Management indicated that selective pricing actions are being considered to offset tariff impacts, but competitive market conditions must be taken into account [36][37] Question: Will tariff impacts affect long-term manufacturing plans? - Management does not expect changes to the overall manufacturing footprint, emphasizing the importance of their global manufacturing network [38] Question: How confident is the company in mitigating tariff impacts? - Management expressed confidence in fully mitigating tariff impacts through various actions, including cost reductions and realigning inventories [43] Question: What underpins the confidence in China's growth rate? - Confidence in mid to high single-digit growth in China is based on strong performance in labs and immunohematology, despite some softness in Triage sales [49] Question: What is the status of the Savanna program? - The company is focused on completing the RBP4x submission to the FDA and is not speculating on outcomes beyond that [45][61] Question: How is the respiratory sales performance impacting guidance? - Management expects to maintain the guidance range for COVID revenue despite a decline, as flu sales have been strong [56][58]

Financial Data and Key Metrics Changes - The company generated $244.7 million of adjusted EBITDA in Q1 2025, down slightly compared to the same quarter last year despite a 20.5% decline in revenue [9][10] - Total adjusted SG&A expenses were $57.5 million, representing 85.6% of gross profit, down from $72.6 million or 87.9% of gross profit in the same quarter last year [10] - Cash outflows from operating activities were $6.9 million for Q1 2025, compared to cash inflows of $17 million for the same period in 2024 [14] Business Line Data and Key Metrics Changes - The Powersports Group sold 13,186 total major units, down 20.5% year over year, with new unit sales down 23.7% and pre-owned unit sales down 13.9% [11] - Gross margins for new units improved to 13.5% from 12.5% year over year, while pre-owned gross margins were 16.3%, down from 19.5% due to an elevated margin in the previous year [11] - Revenue from the powersports dealership group was $239.2 million, down 18.5% year over year, primarily due to lower major unit volume [13] Market Data and Key Metrics Changes - The asset-light vehicle transportation services segment, Wholesale Express, saw revenue decline by 61.5% year over year, with gross profit decreasing 68.6% to $1.1 million [14] - The overall decline in unit sales during the quarter impacted revenue and gross profit across various segments [12] Company Strategy and Development Direction - The company is focused on improving operational discipline and customer service, aiming for long-term financial success despite current challenges [8] - New key management additions are expected to strengthen the company's market position and align with strategic growth goals [6][7] - The company is actively evaluating opportunities to optimize its capital structure and lower its cost of capital [15] Management's Comments on Operating Environment and Future Outlook - The operating environment remains challenging due to tariffs and shifting consumer preferences, but the company is seeing robust demand in the pre-owned segment [7][8] - Management expressed confidence in the actions taken to position the company for long-term success, despite a difficult macroeconomic backdrop [4][8] Other Important Information - The company is engaged in a comprehensive search for a new CFO to lead future growth [6] - The company has fully repaid $38.8 million of convertible notes due on January 2 [14] Q&A Session Summary Question: How aggressive does the company want to be with the cash offer tool for pre-owned inventory? - The company can be aggressive with the cash offer tool, but it depends on the quality of the inventory available [17][18] Question: What are the expectations for inventory levels by year-end? - The company expects inventory levels to be about where they ended in 2024, possibly a little higher due to inflation [20][22] Question: What is the message from OEM partners regarding tariffs? - OEMs are currently absorbing tariff costs, and there is hope for a return to normal operating conditions soon [25][26]

Financial Data and Key Metrics Changes - The company achieved sales of approximately $168 million for the first quarter, with organic sales up 2.8% compared to the previous year [8][9] - Adjusted diluted earnings per share were $0.26, and adjusted EBITDA was approximately $22 million, with adjusted gross margins at 56.7% [9] - The balance sheet remains strong with $97 million in cash and $107 million in debt as of March 31 [9] Business Line Data and Key Metrics Changes - The Specialty Nutrition Systems segment grew almost 9% organically compared to the prior year, reaffirming its leading position in long-term, short-term, and neonatal internal feeding [13] - The Pain Management and Recovery segment saw normalized organic sales up 2.4%, with the radiofrequency ablation business posting near double-digit growth [15][16] - The hyaluronic acid injections and intravenous infusion product lines reported a decline of over 30% due to pricing pressures [18] Market Data and Key Metrics Changes - The company anticipates a softer Q2 for the Specialty Nutrition Systems segment due to distributor order timing but remains confident in its strength for the rest of the year [19] - The impact of tariffs is expected to be significant, with an estimated $15 million in incremental tariff-related manufacturing costs for the year [20][22] Company Strategy and Development Direction - The company is focused on transformation efforts around portfolio, organization structure, and cost management to enhance growth [6][10] - Strategic M&A opportunities are being pursued to align with return criteria, with two smaller transactions already closed this year [10] - The organizational focus has been refined to improve operating processes and capitalize on growth opportunities [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong start to the year, particularly in strategic segments, despite a dynamic economic environment [23] - The revised adjusted EPS estimate reflects a reasonable view of the tariff impact on full-year results [23] - The company is actively monitoring the tariff situation and executing initiatives to reduce risks [23] Other Important Information - The company has transitioned to reporting under two operating segments: Specialty Nutrition Systems and Pain Management and Recovery [11] - A disciplined cost management culture has been embedded to help offset tariff pressures [19] Q&A Session Summary Question: Thoughts on second quarter performance relative to the first - Management indicated that while Q2 may see a slight decline due to distributor order dynamics, they maintain confidence in full-year guidance [28][30] Question: Insights on leadership experience and strategic focus - The new CEO emphasized a focus on optimizing commercial strategies and partnerships to enhance market position [35][36] Question: Clarification on tariff assumptions and impacts - Management provided details on expected tariff-related costs and mitigation strategies, including leveraging international agreements [41][44]

Summary of Key Points from the Conference Call on China Healthcare Equities Industry Overview - The conference focused on the **China Healthcare sector**, particularly the impact of US tariffs on the pharmaceutical supply chain and related industries [2][21]. Core Insights - **Tariff Impact Ranking**: The impact of tariffs is expected to be highest on medical consumables, followed by devices and drugs [2]. - **Timeline for Tariffs**: Tariffs on US pharmaceutical imports may commence within one to two months due to ongoing investigations [2]. - **Impact on Exporters**: Small and medium-sized exporters of low-end medical consumables are anticipated to be most affected, with major CDMOs like Wuxi AppTec, Pharmaron, and Genscript facing 30-50% revenue exposure to the US [2][21]. - **Risk Management**: Large companies are managing risks through planned production capacity shifts to ASEAN/Europe and maintaining high inventory levels (two to three years) [2]. - **API Exporters**: The risk for API exporters is considered manageable in the short term due to China's established supply chain role, despite having double-digit US revenue exposure [2]. Financial Projections - **Revenue and Profit Margin Erosion**: Scenario analysis indicates potential revenue and net profit margin erosion of approximately 5% and 1 percentage point across sub-sectors due to tariffs [3]. - **CDMO Impact**: CDMOs could see up to a 6% revenue impact and a 5-10% decrease in net profit margins [3]. - **Cost Inflation**: Import-dependent segments, such as IVD reagents, may experience around 1% cost inflation, slightly squeezing margins [3]. Market Dynamics - **Global Supply Chain Shifts**: The global supply chain is shifting, but short-term offsets are expected due to stockpiling [2]. - **Domestic Substitution**: There is an expectation of accelerating domestic substitution in the MedTech sector due to import weaknesses caused by tariffs [9]. - **Market Concentration**: A higher level of market concentration is anticipated in the MedTech subsector [9]. Company-Specific Insights - **Limited US Exposure**: Chinese innovative drugs are forecasted to have almost no sales exposure to the US, with limited impact from R&D cost increases due to higher export prices [7]. - **CDMO Resilience**: CDMOs are expected to manage tariff impacts effectively, with 80% of tariff expenses potentially passed through to US clients [8]. - **MedTech Companies**: Companies like Mindray and United Imaging are expected to face low single-digit cost impacts due to their low US exposure [9]. Export Data - **China Healthcare Exports**: Total exports from the China Healthcare sector reached **USD 107.99 billion** in 2024, marking a **5.8% year-on-year increase** [15]. - **Export Composition**: APIs accounted for approximately **40%** of total exports, while IVDs made up **21%** [15][18]. Conclusion - The China Healthcare sector is navigating potential tariff impacts with strategic adjustments and risk management practices. While certain sub-sectors may face challenges, the overall resilience of the industry, particularly in API production and innovative drug development, is expected to mitigate significant adverse effects.

Financial Data and Key Metrics Changes - JBT Morell's first quarter revenue exceeded guidance by $19 million, driven by better-than-expected equipment shipments and strong recurring revenue [17] - Adjusted EBITDA margin was 13.1%, outperforming guidance by 60 basis points, attributed to volume flow-through, favorable mix, and good expense control [17] - Free cash flow for the quarter was $18 million, including approximately $42 million in one-time M&A related payments [19] Business Line Data and Key Metrics Changes - JBT segment revenue increased by 4% year over year, or 5.6% on a constant currency basis, with adjusted EBITDA of $61 million, a 6% increase [18] - MRL segment revenue was flat year over year but grew by 2% on a constant currency basis, with adjusted EBITDA increasing by 19% to $51 million [19] Market Data and Key Metrics Changes - Demand from the poultry industry continued to recover, contributing to a 12% year-over-year increase in orders [6] - The company experienced broad-based strength across global regions, with healthy orders in meat, beverage, pharma, and pet food [6] Company Strategy and Development Direction - The company is focused on integrating its operations to enhance service capabilities and product offerings, positioning itself as a leader in sustainable food solutions [15] - JBT Morell is taking actions to mitigate tariff impacts, including securing concessions from suppliers and implementing selective pricing actions [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to manage near-term impacts from tariffs and macroeconomic uncertainty, highlighting the resilience of recurring revenue [11][23] - The company has temporarily suspended full-year financial guidance due to uncertainty but provided second-quarter guidance, expecting revenue of $885 million to $915 million [22] Other Important Information - The estimated annualized cost impact from tariffs is approximately $50 million to $60 million, with efforts underway to mitigate these costs [10] - The company is on track to achieve targeted cost synergies of $150 million by the end of 2027 [20] Q&A Session Summary Question: Update on guidance and customer behavior - Management indicated that the decision to pull full-year guidance was due to lack of clarity in the environment, with no significant changes in customer behavior noted [26][28] Question: Backlog and order delays - Management clarified that the backlog was affected by foreign exchange and adjustments during the integration of the two businesses, with no cancellations reported [45] Question: Recurring revenue and digital offerings - The increase in recurring revenue above 50% was primarily due to seasonality in equipment revenue recognition, with ongoing efforts to integrate digital offerings [66] Question: Cost mitigation strategies - Management discussed various strategies to mitigate tariff impacts, including reallocating demand to domestic suppliers and adjusting purchasing strategies [78][80] Question: Integration progress and potential demand changes - Management expressed confidence in managing costs and achieving synergies, but noted that lower demand could impact material purchasing and synergy savings [92]